1.
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
by Guy, Bruno
Vaccine, 2009, Vol.28 (3), p.632-649
2.
SARS vaccines: where are we?
by Roper, Rachel L
Expert review of vaccines, 2009-07-01, Vol.8 (7), p.887-898
3.
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
by Guy, Bruno
Vaccine, 2011, Vol.29 (42), p.7229-7241
4.
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
by Stanley, Daphne A
Nature medicine, 2014-10, Vol.20 (10), p.1126-1129
5.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 rand...
by Pitisuttithum, Punnee
The Lancet infectious diseases, 2018-11, Vol.18 (11), p.1260-1268
6.
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
by Bernstein, David I
Vaccine, 2015, Vol.34 (3), p.313-319
7.
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
by Feldmann, Heinz
Nature medicine, 2005-07, Vol.11 (7), p.786-790
8.
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults
by Schmidt, Clint S
Vaccine, 2012, Vol.30 (52), p.7594-7600
9.
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
by Bakari, Muhammad
Vaccine, 2011, Vol.29 (46), p.8417-8428
10.
11.
Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development
by Cheng, Cheng
Vaccine, 2015, Vol.33 (51), p.7344-7351
12.
Construction of a triple gene-deleted Chinese Pseudorabies virus variant and its efficacy study as a vaccine candidate on suckling piglets
by Zhang, Chaolin
Vaccine, 2015, Vol.33 (21), p.2432-2437
13.
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
by Coleman, Christopher M
Vaccine, 2017, Vol.35 (12), p.1586-1589
14.
Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
by Stylianou, E
Vaccine, 2015, Vol.33 (48), p.6800-6808
15.
16.
17.
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
by Glenn, Gregory M
Vaccine, 2012, Vol.31 (3), p.524-532
18.
19.
DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice
by Chi, Hang
Vaccine, 2017, Vol.35 (16), p.2069-2075
20.
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment
by Clarke, David K
Vaccine, 2016, Vol.34 (51), p.6597-6609
